Lamin mutation location predicts cardiac phenotype severity: combined analysis of the published literature

Objective Two LMNA genotype–phenotype cardiac correlations are reported: first, that cardiac involvement in multisystem laminopathies prevails with mutations upstream of the nuclear localisation signal (NLS); second, that worse outcomes occur with non-missense (compared with missense) mutations. We tested whether LMNA mutation DNA location and mutation subtype can predict phenotype severity in patients with lamin heart disease. Methods We used a semantic workflow platform and manual electronic literature search to identify published LMNA mutations with cardiac-predominant phenotype. Hierarchical cluster analysis (HCA) assembled lamin heart disease into classes based on phenotype severity. 176 reported causative mutations were classified and any relationships to mutation location/subtype assessed by contingency analysis. Results More adverse phenotype was associated with mutation location upstream of the NLS (p=0.014, OR 2.38, 95% CI 1.19 to 4.80) but not with non-missense mutations (p=0.337, OR 1.36, 95% CI 0.72 to 2.57), although an association with non-missense mutations was identified in a subcluster with malignant ventricular arrhythmia (p=0.005, OR 2.64, 95% CI 0.76 to 9.21). HCA limited to the 65 mutations described on ClinVar as pathogenic/likely pathogenic showed similar findings (upstream of NLS, p=0.030, OR 4.78, 95% CI 1.28 to 17.83; non-missense, p=0.121, OR 2.64, 95% CI 0.76 to 9.21) as did analysis limited to pathogenic/likely pathogenic variants according to the American College of Medical Genetics and Genomics standards. Conclusion Cardiac patients with an LMNA mutation located upstream versus downstream of the NLS have a more adverse cardiac phenotype, and some missense mutations can be as harmful as non-missense ones.

[1]  Matthew R. Pocock,et al.  Taverna: a tool for the composition and enactment of bioinformatics workflows , 2004, Bioinform..

[2]  M. Laakso,et al.  A novel mutation, Ser143Pro, in the lamin A/C gene is common in finnish patients with familial dilated cardiomyopathy. , 2004, European heart journal.

[3]  H. Crijns,et al.  Meta-analysis of clinical characteristics of 299 carriers of LMNA gene mutations: do lamin A/C mutations portend a high risk of sudden death? , 2004, Journal of Molecular Medicine.

[4]  M. Tekin,et al.  Evidence for single origins of 35delG and delE120 mutations in the GJB2 gene in Anatolia , 2004, Clinical genetics.

[5]  R. Hegele LMNA mutation position predicts organ system involvement in laminopathies , 2005, Clinical genetics.

[6]  Alexandra Paillusson,et al.  A GFP-based reporter system to monitor nonsense-mediated mRNA decay , 2005, Nucleic acids research.

[7]  Tatiana A. Tatusova,et al.  Entrez Gene: gene-centered information at NCBI , 2004, Nucleic Acids Res..

[8]  P. Rahko,et al.  Lamin A/C mutation analysis in a cohort of 324 unrelated patients with idiopathic or familial dilated cardiomyopathy. , 2008, American heart journal.

[9]  L. Tavazzi,et al.  Long-term outcome and risk stratification in dilated cardiolaminopathies. , 2008, Journal of the American College of Cardiology.

[10]  L. Mestroni,et al.  Lamin A/C gene and the heart: how genetics may impact clinical care. , 2008, Journal of the American College of Cardiology.

[11]  A. Zwinderman,et al.  Risk factors for malignant ventricular arrhythmias in lamin a/c mutation carriers a European cohort study. , 2012, Journal of the American College of Cardiology.

[12]  A. Zwinderman,et al.  Gender‐specific differences in major cardiac events and mortality in lamin A/C mutation carriers , 2013, European journal of heart failure.

[13]  L. Maggi,et al.  Overlapping syndromes in laminopathies: a meta-analysis of the reported literature , 2013, Acta myologica : myopathies and cardiomyopathies : official journal of the Mediterranean Society of Myology.

[14]  P. Stenson,et al.  The Human Gene Mutation Database: building a comprehensive mutation repository for clinical and molecular genetics, diagnostic testing and personalized genomic medicine , 2013, Human Genetics.

[15]  V. Fuster,et al.  The MOGE(S) classification of cardiomyopathy for clinicians. , 2014, Journal of the American College of Cardiology.

[16]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[17]  Karim Benkirane,et al.  Comparison of DNA methylation profiles in human fetal and adult red blood cell progenitors , 2015, Genome Medicine.

[18]  Kan Cao,et al.  Nuclear localization signal deletion mutants of lamin A and progerin reveal insights into lamin A processing and emerin targeting , 2014, Nucleus.

[19]  Bale,et al.  Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology , 2015, Genetics in Medicine.

[20]  Yolanda Gil,et al.  Use of semantic workflows to enhance transparency and reproducibility in clinical omics , 2015, Genome Medicine.

[21]  Michael J E Sternberg,et al.  The Phyre2 web portal for protein modeling, prediction and analysis , 2015, Nature Protocols.

[22]  Linda Jo Bone Jeng,et al.  An openly available online tool for implementing the ACMG/AMP standards and guidelines for the interpretation of sequence variants , 2016, Genetics in Medicine.

[23]  Andrea Mazzanti,et al.  2015 ESC Guidelines for the Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death. , 2016, Revista espanola de cardiologia.

[24]  W. Stevenson,et al.  Multicenter Experience With Catheter Ablation for Ventricular Tachycardia in Lamin A/C Cardiomyopathy , 2016, Circulation. Arrhythmia and electrophysiology.

[25]  James Y. Zou Analysis of protein-coding genetic variation in 60,706 humans , 2015, Nature.

[26]  Ricardo Villamarín-Salomón,et al.  ClinVar: public archive of interpretations of clinically relevant variants , 2015, Nucleic Acids Res..

[27]  W. Stevenson,et al.  Long-Term Arrhythmic and Nonarrhythmic Outcomes of Lamin A/C Mutation Carriers. , 2016, Journal of the American College of Cardiology.

[28]  S. Heymans,et al.  Proposal for a revised definition of dilated cardiomyopathy, hypokinetic non-dilated cardiomyopathy, and its implications for clinical practice: a position statement of the ESC working group on myocardial and pericardial diseases. , 2016, European heart journal.

[29]  E. Arbustini,et al.  LMNA Mutations Associated With Mild and Late-Onset Phenotype: The Case of the Dutch Founder Mutation p.(Arg331Gln) , 2017, Circulation. Cardiovascular genetics.

[30]  W. Shimizu,et al.  Gene-Based Risk Stratification for Cardiac Disorders in LMNA Mutation Carriers , 2017, Circulation. Cardiovascular genetics.

[31]  E. Arbustini,et al.  Lamin and the heart , 2017, Heart.